<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181674</url>
  </required_header>
  <id_info>
    <org_study_id>REMIT Pilot</org_study_id>
    <secondary_id>Control # 139433, 143584</secondary_id>
    <secondary_id>10-346</secondary_id>
    <nct_id>NCT01181674</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)</brief_title>
  <official_title>Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot trial is to determine whether an intensive treatment with insulin
      glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients
      with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot trial of 125 patients allocated to either usual care (1/3), 2 months or 4
      months of intensive lifestyle and pharmacotherapy followed by cessation of all drug therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normoglycemia on Therapy</measure>
    <time_frame>(1) 8 weeks and (2) 16 weeks</time_frame>
    <description>Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.
Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.
Normoglycemia on therapy is defined as a mean fasting capillary blood glucose &lt;/=5.4 mmol/L and a mean 2-hour pc blood glucose &lt;/=6.8 mmol/L on 2 seven-point glucose profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.</measure>
    <time_frame>(1) 20 weeks and (2) 28 weeks</time_frame>
    <description>Normal glucose tolerance is defined as a fasting plasma glucose &lt;6.1 mmol/L and a 2-hour pc plasma glucose &lt;7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Fasting Plasma Glucose</measure>
    <time_frame>52 weeks</time_frame>
    <description>Normal fasting plasma glucose is defined as &lt;6.1 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose From Baseline</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>8, 20, 28 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight From Baseline</measure>
    <time_frame>Baseline, 8, 20, 28 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Hypoglycemic Episodes</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Hypoglycemic Episodes</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1 (short)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (long)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>sc injection</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle therapy</intervention_name>
    <description>diet and exercise</description>
    <arm_group_label>Group 1 (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>sc injection</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acarbose</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle therapy</intervention_name>
    <description>diet and exercise</description>
    <arm_group_label>Group 2 (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard glycemic care</intervention_name>
    <description>as informed by the current clinical practice guidelines</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive

          2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient
             enrollment

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization

          4. HbA1C ≤ 8.5% on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on
             half-maximal doses of 2 agents

          5. body mass index ≥ 23 kg/m2

          6. a negative pregnancy test and an agreement to use a reliable method of birth control
             for the duration of the trial in all females with childbearing potential

          7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)

          8. ability and willingness to self-inject insulin

          9. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance

          3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l

          4. history of lactic acidosis or diabetic ketoacidosis

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment

          6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel
             surgery, or predisposition to bowel obstruction

          7. cardiovascular disease including any of:

               -  systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;105 mmHg

               -  peripheral vascular disease

               -  left bundle branch block or third degree AV block

               -  tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate

               -  stenotic valvular heart disease

               -  cardiomyopathy

               -  history of heart failure

               -  history of aortic dissection

               -  documented history of angina or coronary artery disease

               -  history of stroke or transient ischemic attack

          8. pulmonary disease with dependence on oxygen

          9. history of any disease requiring intermittent or continuous systemic glucocorticoid
             treatment

         10. history of any major illness with a life expectancy of &lt;3 years

         11. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity

         12. any history of excessive alcohol intake, acute or chronic

         13. known hypersensitivity to metformin, acarbose, or insulin glargine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hertzel Gerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia McInnes (nee Yakubovich), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University Medical Centre, Diabetes Care and Research Program</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, Balasubramanian K, Hall S, Gerstein HC. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1596-1605. doi: 10.1210/jc.2016-3373.</citation>
    <PMID>28324049</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>May 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2020</results_first_posted>
  <last_update_submitted>May 10, 2020</last_update_submitted>
  <last_update_submitted_qc>May 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Dr. Hertzel Gerstein</investigator_full_name>
    <investigator_title>Director, Division of Endocrinology and Metabolism, McMaster University</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glargine</keyword>
  <keyword>Metformin</keyword>
  <keyword>Acarbose</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (Short)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Long)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="P3">
          <title>Standard Care</title>
          <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26">28 included in analyses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (Short)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Long)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="B3">
          <title>Standard Care</title>
          <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="9.2"/>
                    <measurement group_id="B2" value="57.9" spread="10.5"/>
                    <measurement group_id="B3" value="58.2" spread="11.1"/>
                    <measurement group_id="B4" value="57.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Normoglycemia on Therapy</title>
        <description>Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.
Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.
Normoglycemia on therapy is defined as a mean fasting capillary blood glucose &lt;/=5.4 mmol/L and a mean 2-hour pc blood glucose &lt;/=6.8 mmol/L on 2 seven-point glucose profiles.</description>
        <time_frame>(1) 8 weeks and (2) 16 weeks</time_frame>
        <population>Primary outcome (1) is reported in Experimental Group 1 and Standard care at 8 weeks. Primary outcome (2) is reported in experimental Group 2 and Standard care at 16 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Normoglycemia on Therapy</title>
          <description>Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.
Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.
Normoglycemia on therapy is defined as a mean fasting capillary blood glucose &lt;/=5.4 mmol/L and a mean 2-hour pc blood glucose &lt;/=6.8 mmol/L on 2 seven-point glucose profiles.</description>
          <population>Primary outcome (1) is reported in Experimental Group 1 and Standard care at 8 weeks. Primary outcome (2) is reported in experimental Group 2 and Standard care at 16 weeks.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Group 1 and Standard care at 8 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Group 2 and Standard care at 16 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.</title>
        <description>Normal glucose tolerance is defined as a fasting plasma glucose &lt;6.1 mmol/L and a 2-hour pc plasma glucose &lt;7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs.</description>
        <time_frame>(1) 20 weeks and (2) 28 weeks</time_frame>
        <population>Outcome (1) is reported in Experimental Group 1 and Standard care at 20 weeks. Outcome (2) is reported in experimental Group 2 and Standard care at 28 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.</title>
          <description>Normal glucose tolerance is defined as a fasting plasma glucose &lt;6.1 mmol/L and a 2-hour pc plasma glucose &lt;7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs.</description>
          <population>Outcome (1) is reported in Experimental Group 1 and Standard care at 20 weeks. Outcome (2) is reported in experimental Group 2 and Standard care at 28 weeks.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Group 1 and Standard care at 20 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Group 2 and Standard care at 28 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Fasting Plasma Glucose</title>
        <description>Normal fasting plasma glucose is defined as &lt;6.1 mmol/L.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Fasting Plasma Glucose</title>
          <description>Normal fasting plasma glucose is defined as &lt;6.1 mmol/L.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose From Baseline</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>FPG was not available for some participants at 52 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose From Baseline</title>
          <population>FPG was not available for some participants at 52 weeks.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.96"/>
                    <measurement group_id="O2" value="-0.64" spread="1.38"/>
                    <measurement group_id="O3" value="0.05" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1C</title>
        <time_frame>8, 20, 28 and 52 weeks</time_frame>
        <population>Some participants did not provide HbA1C values.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1C</title>
          <population>Some participants did not provide HbA1C values.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="0.5"/>
                    <measurement group_id="O2" value="6.0" spread="0.4"/>
                    <measurement group_id="O3" value="6.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.4"/>
                    <measurement group_id="O2" value="6.1" spread="0.3"/>
                    <measurement group_id="O3" value="6.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.8"/>
                    <measurement group_id="O2" value="6.4" spread="0.5"/>
                    <measurement group_id="O3" value="6.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="0.8"/>
                    <measurement group_id="O2" value="6.7" spread="0.7"/>
                    <measurement group_id="O3" value="6.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight From Baseline</title>
        <time_frame>Baseline, 8, 20, 28 and 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight From Baseline</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="23.3"/>
                    <measurement group_id="O2" value="95.3" spread="15.2"/>
                    <measurement group_id="O3" value="89.3" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" spread="21.8"/>
                    <measurement group_id="O2" value="92.4" spread="15.0"/>
                    <measurement group_id="O3" value="87.1" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="21.1"/>
                    <measurement group_id="O2" value="90.5" spread="14.8"/>
                    <measurement group_id="O3" value="86.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" spread="20.6"/>
                    <measurement group_id="O2" value="91.7" spread="15.2"/>
                    <measurement group_id="O3" value="86.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" spread="21.7"/>
                    <measurement group_id="O2" value="93.8" spread="16.4"/>
                    <measurement group_id="O3" value="86.5" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Hypoglycemic Episodes</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Hypoglycemic Episodes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Hypoglycemic Episodes</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (Short)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Long)</title>
            <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
          </group>
          <group group_id="O3">
            <title>Standard Care</title>
            <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypoglycemic Episodes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Short)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Long)</title>
          <description>insulin glargine: sc injection
metformin: oral administration
acarbose: oral administration
lifestyle therapy: diet and exercise</description>
        </group>
        <group group_id="E3">
          <title>Standard Care</title>
          <description>Standard glycemic care: as informed by the current clinical practice guidelines</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Natalia McInnes (nee Yakubovich)</name_or_title>
      <organization>McMaster University</organization>
      <phone>905-521-2100</phone>
      <email>natalia.mcinnes@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

